Stock Track | Caris Life Sciences Soars 28.57% in Nasdaq Debut Following Successful $494 Million IPO

Stock Track

Jun 19, 2025

Caris Life Sciences Inc. (CAI), a leading AI-driven precision medicine company specializing in cancer diagnostics, saw its stock soaring 28.57% in its Nasdaq debut on Wednesday. The impressive surge comes on the heels of the company's successful initial public offering (IPO) that raised $494 million, pricing above its marketed range.

The Irving, Texas-based firm sold 23.5 million shares at $21 each, surpassing its proposed range of $19 to $20, which was already an increase from the initial $16 to $18 range. At the IPO price, Caris Life Sciences commanded a market valuation of approximately $5.9 billion. The strong investor interest was evident as the stock was indicated to open at $28.50, representing a significant premium over its IPO price.

Founded in 2008, Caris Life Sciences leverages artificial intelligence and machine learning to analyze oncology data for improved cancer diagnosis and treatment monitoring. The company's successful debut comes at a time when health-care and biotechnology IPOs have been relatively scarce in 2025, highlighting the market's appetite for innovative medical technology firms. The robust performance of Caris Life Sciences in its first day of trading signals strong investor confidence in the company's AI-driven approach to precision medicine and its potential to revolutionize cancer diagnostics and treatment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1184390081"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1184390081\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1184390081?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-19 00:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184390081","market":"nz","top_or_hot":-1,"title":"Stock Track | Caris Life Sciences Soars 28.57% in Nasdaq Debut Following Successful $494 Million IPO","media":"Stock Track","content":"<p>Caris Life Sciences Inc. (CAI), a leading AI-driven precision medicine company specializing in cancer diagnostics, saw its stock soaring 28.57% in its Nasdaq debut on Wednesday. The impressive surge comes on the heels of the company's successful initial public offering (IPO) that raised $494 million, pricing above its marketed range.</p>\n\n<p>The Irving, Texas-based firm sold 23.5 million shares at $21 each, surpassing its proposed range of $19 to $20, which was already an increase from the initial $16 to $18 range. At the IPO price, Caris Life Sciences commanded a market valuation of approximately $5.9 billion. The strong investor interest was evident as the stock was indicated to open at $28.50, representing a significant premium over its IPO price.</p>\n\n<p>Founded in 2008, Caris Life Sciences leverages artificial intelligence and machine learning to analyze oncology data for improved cancer diagnosis and treatment monitoring. The company's successful debut comes at a time when health-care and biotechnology IPOs have been relatively scarce in 2025, highlighting the market's appetite for innovative medical technology firms. The robust performance of Caris Life Sciences in its first day of trading signals strong investor confidence in the company's AI-driven approach to precision medicine and its potential to revolutionize cancer diagnostics and treatment.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Caris Life Sciences Soars 28.57% in Nasdaq Debut Following Successful $494 Million IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Caris Life Sciences Soars 28.57% in Nasdaq Debut Following Successful $494 Million IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-06-19 00:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Caris Life Sciences Inc. (CAI), a leading AI-driven precision medicine company specializing in cancer diagnostics, saw its stock soaring 28.57% in its Nasdaq debut on Wednesday. The impressive surge comes on the heels of the company's successful initial public offering (IPO) that raised $494 million, pricing above its marketed range.</p>\n\n<p>The Irving, Texas-based firm sold 23.5 million shares at $21 each, surpassing its proposed range of $19 to $20, which was already an increase from the initial $16 to $18 range. At the IPO price, Caris Life Sciences commanded a market valuation of approximately $5.9 billion. The strong investor interest was evident as the stock was indicated to open at $28.50, representing a significant premium over its IPO price.</p>\n\n<p>Founded in 2008, Caris Life Sciences leverages artificial intelligence and machine learning to analyze oncology data for improved cancer diagnosis and treatment monitoring. The company's successful debut comes at a time when health-care and biotechnology IPOs have been relatively scarce in 2025, highlighting the market's appetite for innovative medical technology firms. The robust performance of Caris Life Sciences in its first day of trading signals strong investor confidence in the company's AI-driven approach to precision medicine and its potential to revolutionize cancer diagnostics and treatment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CAI","symbol_name":"Caris Life Sciences, Inc.","start_time":0,"source_url":"","article_id":"1184390081","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184390081","pubTimestamp":1750264124,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Caris Life Sciences Inc. , a leading AI-driven precision medicine company specializing in cancer diagnostics, saw its stock soaring 28.57% in its Nasdaq debut on Wednesday. The impressive surge comes on the heels of the company's successful initial public offering  that raised $494 million, pricing above its marketed range.Founded in 2008, Caris Life Sciences leverages artificial intelligence and machine learning to analyze oncology data for improved cancer diagnosis and treatment monitoring. Th","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CAI":"Caris Life Sciences, Inc."},"translate_title":"Caris Life Sciences在纳斯达克首次公开募股成功4.94亿美元后股价飙升28.57%","themeId":"d005a2f9a47d099d0e2bd1b2ead6e0c5","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAI":1},"content_text":"Caris Life Sciences Inc. (CAI), a leading AI-driven precision medicine company specializing in cancer diagnostics, saw its stock soaring 28.57% in its Nasdaq debut on Wednesday. The impressive surge comes on the heels of the company's successful initial public offering (IPO) that raised $494 million, pricing above its marketed range.\nThe Irving, Texas-based firm sold 23.5 million shares at $21 each, surpassing its proposed range of $19 to $20, which was already an increase from the initial $16 to $18 range. At the IPO price, Caris Life Sciences commanded a market valuation of approximately $5.9 billion. The strong investor interest was evident as the stock was indicated to open at $28.50, representing a significant premium over its IPO price.\nFounded in 2008, Caris Life Sciences leverages artificial intelligence and machine learning to analyze oncology data for improved cancer diagnosis and treatment monitoring. The company's successful debut comes at a time when health-care and biotechnology IPOs have been relatively scarce in 2025, highlighting the market's appetite for innovative medical technology firms. The robust performance of Caris Life Sciences in its first day of trading signals strong investor confidence in the company's AI-driven approach to precision medicine and its potential to revolutionize cancer diagnostics and treatment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}